<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365085">
  <stage>Registered</stage>
  <submitdate>1/10/2013</submitdate>
  <approvaldate>2/10/2013</approvaldate>
  <actrnumber>ACTRN12613001102763</actrnumber>
  <trial_identification>
    <studytitle>STARflo Glaucoma Implant for Open Angle Glaucoma</studytitle>
    <scientifictitle>A Prospective Single Centre Phase 4 Trial to Evaluate the Safety and Efficacy of the STARflo Glaucoma Implant in Patients with Open Angle Glaucoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Open-Angle Glaucoma</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Implantation of STARflo glaucoma implant into the anterior chamber and suprachoroidal space. The STARflo glaucoma implant (v2.0) is a 5mm x 8mm silicone device made using a patented porous biomatrix designed to facilitate the flow of aqueous fluid through it and enhance compatibility with surrounding tissues. Implantation is performed via an external approach under local anaesthesia and is anticipated to take 45 - 60 minutes.</interventions>
    <comparator>Glaucoma control prior to surgery</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Surgery</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Intraocular Pressure using Goldmann applanation tonometry</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Visual Acuity using snellen acuity charts</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visual Field using automated perimetry</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of glaucoma medications (patient self report and documented by treating doctor)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (GQL-15 Quality of Life Questionnaire)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Males or females 18 years of age or greater.
2. Diagnosis of open angle glaucoma in the study eye.
3. Concurrent treatment with ocular hypotensive medications in the study eye and/or oral acetazolamide.
4. Documented IOP &gt; or = 21 mmHg in the study eye on medical therapy at two visits at least 48 hours apart, within six weeks prior to study entry and at day 0. 
5. Glaucoma progression despite current medical and/or laser trabeculoplasty treatment OR intolerance of current medical and/or laser trabeculoplasty treatment OR inadequate IOP reduction with medical and/or laser trabeculoplasty treatment.
6. Patient willing and able to undergo implantation of the STARflo in the study eye and return for scheduled study-related examinations.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Diagnosis of secondary open angle glaucoma where STARflo implant is considered contraindicated (e.g., traumatic, uveitic, or neovascular glaucoma).
2. Diagnosis of angle-closure glaucoma or angle-closure suspect
Clinically significant corneal disease (e.g., corneal dystrophy, corneal graft)
3. Any previous ophthalmic surgery in the same eye quadrant other than trabeculectomy, trabeculoplasty, and cataract surgery within 3 months prior to study entry. 
4. Laser trabeculoplasty within three months prior to study.
Active vascular or inflammatory retinopathy (diabetes, hypertension, uveitis)
5. Intra-ocular inflammation or infection within six months prior to study
6. Evidence of crystalline lens subluxation or luxation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>All patients identified by participating specialists deemed to require surgery for glaucoma management and meeting inclusion/exclusion criteria will be offered participation. </concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Sydney Hospital and Sydney Eye Hospital - Sydney</hospital>
    <postcode>2000 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>South East Sydney Illawarra Area Health Service</primarysponsorname>
    <primarysponsoraddress>Edmund Blacket Building
Prince of Wales Hospital
Cnr High Street and Avoca Street
Randwick NSW 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Assess the intraocular pressure (IOP) reduction induced by the STARflo glaucoma implant in eyes with open angle glaucoma. Absolute success is defined as an IOP &lt; 21mmHg and &gt; 5mmHg with a minimum 20% IOP reduction from baseline without the need for glaucoma medication. Qualified success is defined as an IOP &lt; 21mmHg and &gt; 5mmHg with a minimum 20% IOP reduction from baseline with the concomitant use of glaucoma medication.


This is a prospective, single centre study of the CE marked and TGA approved STARflo glaucoma implant. Patients with open angle glaucoma requiring surgical reduction of IOP will be screened for suitability for inclusion in the study. Following implantation of the STARflo, participants will be followed for a minimum 12-months.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SESLHD Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Support Office
G71, East Wing 
Edmund Blacket Building
Prince of Wales Hospital
Cnr High Street and Avoca Street
Randwick NSW 2031</ethicaddress>
      <ethicapprovaldate />
      <hrec>13/253</hrec>
      <ethicsubmitdate>8/10/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Colin Clement</name>
      <address>Glaucoma Unit
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000</address>
      <phone>+612 9382 7111</phone>
      <fax />
      <email>colinandkylie@me.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Colin Clement</name>
      <address>Glaucoma Unit
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000</address>
      <phone>+612 9382 7111</phone>
      <fax />
      <email>colinandkylie@me.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Colin Clement</name>
      <address>Glaucoma Unit
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000</address>
      <phone>+612 9382 7111</phone>
      <fax />
      <email>colinandkylie@me.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Colin Clement</name>
      <address>Glaucoma Unit
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000</address>
      <phone>+612 9382 7111</phone>
      <fax />
      <email>colinandkylie@me.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>